Antisense & RNAi Therapeutics Global Market Report 2026

Description

Antisense therapy involves the selective, sequence-specific suppression of gene expression using single-stranded DNA oligonucleotides. In contrast, RNA interference (RNAi) is triggered by double-stranded RNA (dsRNA) and leads to sequence-specific degradation of target single-stranded mRNAs.

The main technologies in antisense and RNAi therapeutics include RNA interference and antisense RNA. RNA interference is a conserved biological mechanism that responds to double-stranded RNA, providing resistance to both endogenous parasitic and exogenous pathogenic nucleic acids while regulating protein-coding gene expression. Routes of administration include pulmonary delivery, intravenous injection, intradermal injection, intraperitoneal injection, topical delivery, and others. These therapies are applied for indications such as oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases, and other conditions.

Tariffs have affected the antisense & rnai therapeutics market by increasing the cost of imported oligonucleotides, delivery devices, and laboratory equipment, thereby creating supply chain disruptions. The impact is most pronounced in regions like north america and europe, which heavily rely on imported biotech components. Segments such as rna interference (rnai) therapeutics and antisense oligonucleotides face higher production costs, while nascent companies may experience delayed product launches. However, tariffs have incentivized local manufacturing and innovation in delivery systems, creating opportunities for domestic production and cost optimization.

The antisense & rnai therapeutics market research report is one of a series of new reports from The Business Research Company that provides antisense & rnai therapeutics market statistics, including antisense & rnai therapeutics industry global market size, regional shares, competitors with a antisense & rnai therapeutics market share, detailed antisense & rnai therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the antisense & rnai therapeutics industry. This antisense & rnai therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antisense & rnai therapeutics market size has grown rapidly in recent years. It will grow from $1.93 billion in 2025 to $2.17 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to early adoption of antisense therapies, initial rnai research breakthroughs, development of oligonucleotide synthesis techniques, growing demand for targeted therapeutics, investments in biotech research.

The antisense & rnai therapeutics market size is expected to see rapid growth in the next few years. It will grow to $3.53 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to advancements in delivery technologies, expansion of precision medicine, integration with ai-driven drug discovery, increasing rnai-based clinical trials, rising healthcare investments in emerging markets. Major trends in the forecast period include targeted gene silencing, novel delivery mechanisms, personalized therapeutics, nucleic acid stabilization techniques, regulatory & clinical advancements.

The rising prevalence of coronary artery disease, neurodegenerative disorders, and infectious diseases is expected to drive the growth of the antisense and RNAi therapeutics market. Gene-silencing approaches, including RNA interference (RNAi) and antisense oligonucleotides, are employed to treat various neurodegenerative conditions by correcting or suppressing mutant gene expression. For instance, in January 2024, the American Heart Association, a US-based organization, reported that the age-adjusted death rate from cardiovascular diseases rose to 233.3 per 100,000, marking a 4.0% increase from the previous year. This trend highlights the growing burden of cardiovascular and related diseases, fueling demand for advanced gene-targeted therapies.

Major companies in the antisense and RNAi therapeutics market are pursuing strategic collaborations and partnerships to accelerate innovation and maintain competitiveness. For example, in January 2023, Orbit Discovery Limited, a US-based peptide discovery company, partnered with SanegeneBio Inc., a UK-based RNAi therapeutics developer, to advance tissue-specific delivery of RNA therapeutics through hit identification and cell-based internalization studies. Orbit's peptide display technology enables rapid discovery of effective therapeutic leads for gene knockdown.

In July 2023, Alnylam, a US-based RNAi therapeutics company, entered a strategic partnership with Roche AG, Switzerland, to co-develop and co-commercialize Zilebesiran, an investigational RNAi therapeutic for hypertension in patients with high cardiovascular risk. This collaboration leverages Alnylam's RNAi expertise and Roche's commercialization capabilities to expand treatment options in cardiovascular disease management.

Major companies operating in the antisense & rnai therapeutics market are Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilac ve SaglIk Urunleri A.S., Egypt Otsuka Pharmaceutical

North America was the largest region in the antisense & RNAi therapeutics market in 2025. The regions covered in the antisense & rnai therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antisense & rnai therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antisense and RNAi therapeutics market includes revenues earned by entities by regulating gene expression at multiple levels, such as replication, transcription, and translation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antisense & RNAi Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses antisense & rnai therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antisense & rnai therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antisense & rnai therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Technology: RNA Interference; Antisense RNA
2) By Route Of Administration: Intravenous Injections; Intra-dermal Injections; Other Delivery Methods
3) By Indication: Oncology; Cardiovascular Diseases (CVDs); Respiratory Disorders; Neurological Disorders; Infectious Diseases; Other Indications
Subsegments:
1) By RNA Interference (RNAi): Small Interfering RNA (siRNA); Short Hairpin RNA (shRNA); Dicer-substrate siRNA; MicroRNA (miRNA) Based Therapeutics
2) By Antisense RNA: Antisense Oligonucleotides (ASOs); Morpholino Oligomers; Locked Nucleic Acids (LNAs); Gapmer Antisense Oligonucleotides
Companies Mentioned: Biogen Inc.; Ionis Pharmaceuticals Inc.; Alnylam Pharmaceuticals Inc.; Arrowhead Pharmaceuticals Inc.; Moderna Inc.; Sanofi S.A.; Dicerna Pharmaceuticals Inc.; Arbutus Biopharma Corporation; Acuitas Therapeutics; Adhera Therapeutics Inc.; EdiGene Inc.; Sirnaomics Inc.; Suzhou Ribo Life Science Co. Ltd; Biocon Limited; Quark Pharmaceuticals; GlaxoSmithKline Plc; Shanghai Junshi Biosciences Co. Ltd.; AstraZeneca; Benitec Biopharma Limited; Silence Therapeutics; Dynacure; CN Bio Innovations; Sarepta Therapeutics; Mallinckrodt; Regeneron Pharmaceuticals Inc.; Alcyone Lifesciences Inc.; Bio-Path Holdings Inc; Calando Pharmaceuticals; Enzon Pharmaceuticals Inc; Celnova Pharma; Pfizer Inc.; Taiba Pharma; Gen Ilac ve SaglIk Urunleri A.S.; Egypt Otsuka Pharmaceutical
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH4MARTN01_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Antisense & RNAi Therapeutics Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Antisense & RNAi Therapeutics Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Antisense & RNAi Therapeutics Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Antisense & RNAi Therapeutics Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.3 Industry 4.0 & Intelligent Manufacturing
- 4.1.4 Artificial Intelligence & Autonomous Intelligence
- 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
- 4.2.1 Targeted Gene Silencing
- 4.2.2 Novel Delivery Mechanisms
- 4.2.3 Personalized Therapeutics
- 4.2.4 Nucleic Acid Stabilization Techniques
- 4.2.5 Regulatory & Clinical Advancements

5. Antisense & RNAi Therapeutics Market Analysis Of End Use Industries

5.1 Hospitals & Clinics
5.2 Pharmaceutical & Biotech Companies
5.3 Research Laboratories
5.4 Academic & Medical Institutes
5.5 Contract Research Organizations (Cros)

6. Antisense & RNAi Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Antisense & RNAi Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Antisense & RNAi Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Antisense & RNAi Therapeutics Market Size, Comparisons And Growth Rate Analysis
7.3. Global Antisense & RNAi Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Antisense & RNAi Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Antisense & RNAi Therapeutics Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Antisense & RNAi Therapeutics Market Segmentation

9.1. Global Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
RNA Interference, Antisense RNA
9.2. Global Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
9.3. Global Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications
9.4. Global Antisense & RNAi Therapeutics Market, Sub-Segmentation Of RNA Interference (RNAi), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics
9.5. Global Antisense & RNAi Therapeutics Market, Sub-Segmentation Of Antisense RNA, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

10. Antisense & RNAi Therapeutics Market Regional And Country Analysis

10.1. Global Antisense & RNAi Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Antisense & RNAi Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Antisense & RNAi Therapeutics Market

11.1. Asia-Pacific Antisense & RNAi Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Antisense & RNAi Therapeutics Market

12.1. China Antisense & RNAi Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Antisense & RNAi Therapeutics Market

13.1. India Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Antisense & RNAi Therapeutics Market

14.1. Japan Antisense & RNAi Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Antisense & RNAi Therapeutics Market

15.1. Australia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Antisense & RNAi Therapeutics Market

16.1. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Antisense & RNAi Therapeutics Market

17.1. South Korea Antisense & RNAi Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Antisense & RNAi Therapeutics Market

18.1. Taiwan Antisense & RNAi Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Antisense & RNAi Therapeutics Market

19.1. South East Asia Antisense & RNAi Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Antisense & RNAi Therapeutics Market

20.1. Western Europe Antisense & RNAi Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Antisense & RNAi Therapeutics Market

21.1. UK Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Antisense & RNAi Therapeutics Market

22.1. Germany Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Antisense & RNAi Therapeutics Market

23.1. France Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Antisense & RNAi Therapeutics Market

24.1. Italy Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Antisense & RNAi Therapeutics Market

25.1. Spain Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Antisense & RNAi Therapeutics Market

26.1. Eastern Europe Antisense & RNAi Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Antisense & RNAi Therapeutics Market

27.1. Russia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Antisense & RNAi Therapeutics Market

28.1. North America Antisense & RNAi Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Antisense & RNAi Therapeutics Market

29.1. USA Antisense & RNAi Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Antisense & RNAi Therapeutics Market

30.1. Canada Antisense & RNAi Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Antisense & RNAi Therapeutics Market

31.1. South America Antisense & RNAi Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Antisense & RNAi Therapeutics Market

32.1. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Antisense & RNAi Therapeutics Market

33.1. Middle East Antisense & RNAi Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Antisense & RNAi Therapeutics Market

34.1. Africa Antisense & RNAi Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Antisense & RNAi Therapeutics Market, Segmentation By Technology, Segmentation By Route Of Administration, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Antisense & RNAi Therapeutics Market Regulatory and Investment Landscape

36. Antisense & RNAi Therapeutics Market Competitive Landscape And Company Profiles

36.1. Antisense & RNAi Therapeutics Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Antisense & RNAi Therapeutics Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Antisense & RNAi Therapeutics Market Company Profiles
- 36.3.1. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Ionis Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Arrowhead Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Antisense & RNAi Therapeutics Market Other Major And Innovative Companies

Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics

38. Global Antisense & RNAi Therapeutics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Antisense & RNAi Therapeutics Market

40. Antisense & RNAi Therapeutics Market High Potential Countries, Segments and Strategies

40.1 Antisense & RNAi Therapeutics Market In 2030 - Countries Offering Most New Opportunities
40.2 Antisense & RNAi Therapeutics Market In 2030 - Segments Offering Most New Opportunities
40.3 Antisense & RNAi Therapeutics Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations
41.2. Currencies
41.3. Historic And Forecast Inflation Rates
41.4. Research Inquiries
41.5. The Business Research Company
41.6. Copyright And Disclaimer